YOLFTbeta
30

Jiangxi Fushine Pharmaceutical Co Ltd

300497 · SHE · Healthcare / Biotechnology

13.60CNY-0.34 (-2.44%)

Price History

Full chart

Market Stats

Previous Close13.94
Open13.98
Day Range13.50 – 14.07
52-Week Range9.37 – 24.11
Volume14.70M
Market Cap9.62B
P/E (TTM)74.42
Forward P/E0.00
EPS0.24
Dividend Yield0.28%
Beta0.17
50-Day Avg18.32
200-Day Avg17.46

About

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancroid. The company also provides tazobactam, piperacillin, sultamicillin, sultamicillin tosylate, tazobactam sodium, sulbactam sodium, sulbactam pivoxil, avibactam sodium, sitafloxacin, torasemide, moxifloxacin hydrochloride, paroxetine hydrochloride, and berberine hydrochloride products. In addition, it offers lithium-ion battery electrolyte additives; and microbial protein, amino acid water-soluble fertilizer, and other bio-fermentation products. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. Jiangxi Fushine Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Jingdezhen, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jizu Cheng
  • Employees1.66K
  • HeadquartersNo. 2, Yuli Industrial Zone, Jingdezhen, China, 333000, China
  • Websitehttps://www.fushine.cn

Leadership

  • Mr. Jian Hua BaoPresident & Chairman · b. 1977
  • Mr. Jizu ChengCEO & Director · b. 1960
  • Mr. Guang YangFinancial Director · b. 1987
  • Ms. Yun PengDeputy GM & Secretary of the Board · b. 1992
  • Mr. Xiang Ming ZhangDeputy General Manager · b. 1975
  • Ms. Ying LiuDeputy General Manager · b. 1981
  • Mr. Haipeng WeiDeputy General Manager · b. 1976
  • Haiyan XieAccounting Supervisor

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue291.37M360.32M442.84M510.73M579.74M763.69M958.15M1.16B1.35B1.49B1.43B1.65B1.61B1.18B1.18B
Growth (%)-+23.67%+22.90%+15.33%+13.51%+31.73%+25.46%+21.42%+16.38%+10.26%-4.25%+15.23%-2.28%-26.83%+0.61%
Cost of Revenue209.11M267.30M327.89M371.27M374.84M437.47M594.66M734.03M773.38M892.31M996.18M1.43B1.47B1.12B986.85M
Gross Profit82.26M93.02M114.95M139.46M204.90M326.22M363.49M429.41M580.67M600.64M433.36M214.38M138.32M53.88M198.14M
Gross Margin28.23%25.82%25.96%27.31%35.34%42.72%37.94%36.91%42.88%40.23%30.31%13.01%8.59%4.57%16.72%
Operating Expense45.45M52.12M67.47M78.62M95.00M138.05M165.90M198.25M211.41M213.65M376.36M348.34M367.71M340.95M259.69M
Operating Income36.81M40.90M47.48M60.83M109.90M188.17M197.59M231.16M369.26M386.99M57.00M-133.95M-229.39M-287.07M-61.55M
Operating Margin12.63%11.35%10.72%11.91%18.96%24.64%20.62%19.87%27.27%25.92%3.99%-8.13%-14.25%-24.37%-5.19%
EBITDA41.85M74.66M79.83M97.27M152.30M246.38M262.02M304.38M459.86M477.33M179.47M23.02M-31.68M-76.34M-61.55M
EBITDA Margin14.36%20.72%18.03%19.04%26.27%32.26%27.35%26.16%33.96%31.97%12.55%1.40%-1.97%-6.48%-5.19%
Net Income35.85M40.08M45.07M53.44M93.60M173.91M177.55M194.72M305.84M319.30M48.83M-141.47M-200.80M-272.10M-53.07M
Net Income Margin12.30%11.12%10.18%10.46%16.15%22.77%18.53%16.74%22.59%21.39%3.42%-8.59%-12.47%-23.10%-4.48%
R&D13.13M13.11M13.99M17.87M18.33M30.90M43.51M52.88M59.46M76.53M78.51M77.45M97.45M74.66M59.50M
R&D as % of Total Revenue4.51%3.64%3.16%3.50%3.16%4.05%4.54%4.54%4.39%5.13%5.49%4.70%6.05%6.34%5.02%
Interest Expense6.48M7.14M9.45M10.43M12.21M8.58M15.77M24.47M34.98M24.58M25.84M41.89M42.03M41.50M46.24M
Interest Expense % of Total Revenue2.22%1.98%2.13%2.04%2.11%1.12%1.65%2.10%2.58%1.65%1.81%2.54%2.61%3.52%3.90%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets352.57M476.31M541.31M632.35M1.01B1.40B1.79B2.20B2.60B4.05B4.68B5.06B4.82B4.54B4.40B
Total Liabilities232.04M291.70M311.55M349.09M413.44M614.20M822.70M1.05B1.07B997.93M1.77B2.37B2.35B2.36B2.20B
Total Equity120.52M184.60M229.76M283.26M596.21M756.02M936.87M1.12B1.49B3.01B2.88B2.68B2.48B2.18B2.18B
Cash55.39M65.59M64.93M62.08M359.78M341.66M612.61M780.70M791.36M1.59B1.27B978.03M729.37M695.35M482.98M
Total Debt83.50M104.74M132.09M159.00M228.20M217.00M432.64M676.59M703.23M442.38M1.00B1.42B1.55B1.29B-
Net Debt28.11M39.15M67.16M96.92M-131.58M-124.66M-179.97M-104.11M-88.13M-1.14B-270.78M439.71M818.72M597.53M897.99M

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow33.80M63.20M57.22M31.39M74.01M188.53M210.72M175.91M337.91M382.35M72.32M-120.85M-64.76M187.64M62.67M
Investing Cash Flow-37.46M-79.26M-74.58M-49.79M-71.94M-252.26M-60.44M-161.44M-351.45M-548.50M-735.48M-508.34M-354.50M-139.61M-
Financing Cash Flow21.92M30.81M15.21M16.07M290.93M28.81M87.27M169.75M30.82M912.69M349.61M282.99M149.76M-87.78M-
Capital Expenditure82.21M51.24M75.60M51.86M73.74M81.34M98.99M163.89M324.90M449.24M679.60M459.41M242.23M141.75M224.88M
Free Cash Flow-48.41M11.95M-18.38M-20.47M264.15K107.20M111.73M12.03M13.01M-66.89M-607.28M-580.26M-306.99M45.89M-162.21M
Dividends Paid5.62M7.10M9.35M9.85M32.84M45.33M70.84M79.74M43.91M56.76M110.00M54.58M55.79M55.50M54.77M
FCF to OCF-143.25%18.91%-32.12%-65.22%0.36%56.86%53.02%6.84%3.85%-17.49%-839.69%480.15%474.02%24.46%-258.81%
Dividend Paid to FCF-11.62%59.39%-50.89%-48.12%12432.44%42.29%63.40%663.00%337.55%-84.87%-18.11%-9.41%-18.17%120.94%-33.76%

Earnings

Report DateFeb 4, 2016Apr 25, 2016Aug 23, 2016Oct 27, 2016Feb 27, 2017Apr 24, 2017Jul 19, 2017Oct 27, 2017Dec 31, 2017Apr 24, 2018Jul 30, 2018Oct 28, 2018Feb 22, 2019Apr 28, 2019Jul 29, 2019Oct 25, 2019Feb 21, 2020Apr 24, 2020Jul 31, 2020Oct 27, 2020Dec 31, 2020Apr 23, 2021Aug 11, 2021Oct 26, 2021Apr 28, 2022Aug 26, 2022Oct 26, 2022Apr 25, 2023Aug 30, 2023Oct 24, 2023Apr 28, 2024Aug 28, 2024Oct 28, 2024Apr 25, 2025Aug 27, 2025Oct 28, 2025Apr 28, 2026Jun 30, 2026
EPS Estimate--0.110.220.47----0.470.130.090.140.170.150.220.14---0.810.81----------------
EPS Actual0.070.090.230.210.190.120.120.090.090.230.160.090.050.100.140.220.180.180.290.160.060.060.140.020.050.030.00-0.39-0.05-0.040.00-0.04-0.07-0.39-0.02-0.100.010.21
Surprise--109.09%-4.55%-59.57%-----51.06%23.08%0.00%-64.29%-41.18%-6.67%0.00%28.57%----92.59%-92.59%----------------
TimingPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market-Pre-market----

Key Statistics & Ratios

Market Cap9.62B
Enterprise Value11.86B
Trailing P/E74.42
Forward P/E0.00
Price / Sales6.17
Price / Book4.55
EPS0.24
Book Value4.39
Revenue (TTM)1.56B
Gross Profit (TTM)440.51M
EBITDA345.27M
Profit Margin8.27%
Operating Margin24.08%
Return on Equity5.20%
Return on Assets2.09%
Shares Outstanding538.65M
Shares Float413.04M
Beta0.17
Dividend Yield0.28%
Dividend Rate0.05
Payout Ratio39.84%

Dividends

20261×
0.05Aug 24, 2026
20211×
0.20Jul 8, 2021
20201×
0.13May 18, 2020
20191×
0.10Jun 6, 2019
20181×
0.13Jul 3, 2018
20171×
0.13Jun 14, 2017
20161×
0.09Jun 17, 2016

Stock Splits

  • May 18, 20201.6:1
  • Jun 6, 20191.2:1
  • Jul 3, 20182:1
  • Sep 23, 201615:10